globenewswire.com · Dec 1, 2025
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP 3 ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP 3 ACT's demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to address large existing global commercial opportunity CAMBRIDGE, Mass. and HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a preclinical biopharmaceutical subsidiary of Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) that is engineering the next generation of peptide conjugate therapeutics, and Texas Biomedical Research Institute (Texas Biomed), one of the world's foremost independent biomedical research institutions dedicated to eradicating infection and advancing health, announce a collaboration to conduct in vitro testing of Decoy's peptide conjugate fusion inhibitors across several influenza strains including H5N1 avian flu.
